You are viewing: Netherlands Oral Proteins & Peptides Market analysis

The Netherlands Oral Proteins & Peptides Market was valued at $54.9 Million in 2025 and projected to reach to $98.9 Million by 2030, representing a compound annual growth rate of 12.5%. The Netherlands oral proteins & peptides market is poised for sustained expansion through 2030, driven by technological advancements in oral delivery systems and growing clinical validation of peptide therapeutics.

Netherlands Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Netherlands Oral Proteins & Peptides Market Trends and Insights

  • This 12.5% compound annual growth rate reflects strong demand for innovative oral delivery solutions in the Netherlands, driven by advances in bioavailability enhancement technologies and increasing adoption of peptide-based therapeutics.
  • The Netherlands' position as a European pharmaceutical hub supports market expansion through research infrastructure and regulatory expertise. In 2025, the Netherlands market benefits from a mature healthcare system and high pharmaceutical R&D investment.
  • By 2030, the Netherlands is expected to capture significant market share as oral peptide formulations address unmet clinical needs in diabetes, gastrointestinal disorders, and metabolic diseases.
  • The Netherlands' commitment to precision medicine and biotechnology innovation positions the country as a key growth market within Europe's oral proteins & peptides sector..

Key Market Statistics

  • CAGR (2025-2030) 12.5% CAGR
  • Market Size, 2025 ~USD 54.9 Million
  • Forecast, 2030 ~USD 98.9 Million
  • Country Netherlands

Netherlands Oral Proteins & Peptides Market Overview

Market Valuation Growth :

The Netherlands oral proteins & peptides market is valued at $54.9 million in 2025, with projections reaching $98.9 million by 2030, representing an 80% increase over the forecast period.

Strong CAGR Performance :

At 12.5% CAGR, the Netherlands market demonstrates robust growth momentum, outpacing many European counterparts and reflecting strong adoption of oral peptide therapeutics in the Dutch healthcare system.

Bioavailability Innovation Hub :

The Netherlands is leveraging advanced bioavailability enhancement technologies, positioning itself as a key market for next-generation oral delivery solutions that improve peptide absorption and therapeutic efficacy.

Peptide Therapeutics Adoption :

Increasing clinical adoption of peptide-based therapeutics across Dutch healthcare institutions is driving market expansion, supported by favorable regulatory frameworks and strong pharmaceutical R&D infrastructure.

Netherlands Oral Proteins & Peptides Market Dynamics

  • Dutch pharmaceutical companies and research institutions are actively investing in bioavailability enhancement technologies, positioning the country as a regional innovation leader.
  • The market benefits from a sophisticated healthcare infrastructure, strong regulatory support, and increasing physician adoption of peptide-based treatments for chronic diseases. Key growth drivers include rising prevalence of metabolic and gastrointestinal disorders, expanding geriatric population requiring innovative therapeutics, and collaborative partnerships between Dutch biotech firms and international pharmaceutical companies.
  • The competitive landscape is intensifying as manufacturers develop novel formulations to overcome oral peptide delivery challenges.
  • By 2030, the Netherlands market is expected to capture significant value within the European oral proteins & peptides segment, supported by continued investment in R&D and favorable reimbursement policies..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Netherlands oral proteins & peptides market valued at $54.9M in 2025, expanding to $98.9M by 2030 at 12.5% CAGR
    • The Netherlands' advanced pharmaceutical infrastructure and R&D capabilities drive adoption of oral peptide therapeutics
    • Bioavailability enhancement technologies are key growth enablers in the Netherlands market through 2030
    • The Netherlands represents a high-potential European market for oral protein and peptide formulation innovation

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Netherlands Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOME CARE SETTINGS19.533.138.142.547.453.159.667.212
    HOSPITALS & SPECIALTY CLINICS5.89.610.91213.114.51617.810.3
    LONG-TERM CARE FACILITIES7.813.11516.718.620.723.22611.6
    TOTAL33.155.763.971.279.188.398.8110.911.6

    Target Audience

    • Pharmaceutical Manufacturers : Manufacturers need Netherlands-specific market data to evaluate market entry opportunities, benchmark competitive positioning, and develop localized product strategies for oral peptide therapeutics in this high-growth European market.
    • Biotech & Contract Research Organizations : Dutch and international biotech firms require detailed market intelligence to identify partnership opportunities, assess clinical adoption rates, and prioritize R&D investments in oral delivery technologies for the Netherlands.
    • Healthcare Investors & Private Equity : Investment firms need country-level market analysis to evaluate acquisition targets, assess portfolio company growth potential, and identify emerging opportunities in the Netherlands oral proteins & peptides sector.
    • Healthcare Consultants & Advisors : Consultants serving pharmaceutical and biotech clients require Netherlands-specific market data to support strategic recommendations, competitive analysis, and market entry planning for oral peptide therapeutics.
    • Government & Healthcare Policy Makers : Dutch healthcare authorities and policy makers need market insights to inform reimbursement decisions, regulatory frameworks, and healthcare innovation strategies for oral proteins & peptides in the Netherlands.

    Key Companies in the Netherlands Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Market-Specific Sizing & Forecasts : Access precise valuation data for the Netherlands market ($54.9M in 2025, $98.9M in 2030) with country-specific CAGR analysis to support investment decisions and business planning in this high-growth segment.
    • Competitive Landscape Intelligence : Understand the Dutch oral proteins & peptides competitive environment, including local biotech players, international entrants, and market consolidation trends specific to the Netherlands healthcare ecosystem.
    • Regulatory & Reimbursement Insights : Gain detailed knowledge of Dutch regulatory pathways, reimbursement policies, and healthcare system dynamics that influence market adoption and pricing strategies for oral peptide therapeutics.
    • Technology & Innovation Trends : Identify emerging bioavailability enhancement technologies and delivery innovations being developed and commercialized within the Netherlands, positioning your strategy ahead of market shifts.
    • Strategic Market Entry Planning : Leverage Netherlands-specific market data to develop targeted go-to-market strategies, identify partnership opportunities with Dutch pharmaceutical firms, and optimize resource allocation for regional expansion.

    Frequently asked questions

    What is the current size of the oral proteins & peptides market in the Netherlands?

    The Netherlands oral proteins & peptides market is valued at $54.9 million in 2025 and is projected to grow to $98.9 million by 2030.

    What is the expected growth rate for the Netherlands market?

    The Netherlands market is expected to grow at a compound annual growth rate (CAGR) of 12.5% from 2025 to 2030.

    What factors are driving growth in the Netherlands oral proteins & peptides market?

    Key drivers include advances in bioavailability enhancement technologies, increasing adoption of peptide-based therapeutics, the Netherlands' strong pharmaceutical R&D infrastructure, and growing demand for precision medicine solutions.

    Which therapeutic areas are most relevant to the Netherlands market?

    The Netherlands market is seeing significant demand in diabetes management, gastrointestinal disorders, and metabolic diseases through oral peptide formulations.

    Why is the Netherlands a strategic market for oral peptide innovation?

    The Netherlands benefits from a mature healthcare system, high pharmaceutical R&D investment, strong regulatory expertise, and a commitment to biotechnology innovation that positions it as a key European growth market.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status